Market Overview

UPDATE: Cantor Fitzgerald Raises PT to $8 on Ironwood Pharmaceuticals; Maintains Sell

Share:
Related IRWD
20 Stocks Which Rallied Three Days On Increasing Volume
BTIG Raises Ironwood Pharmaceuticals Price Target Ahead Of New Drug Launch

Cantor Fitzgerald reiterated its Sell rating on Ironwood Pharmaceuticals, (NASDAQ: IRWD) but raised its price target from $7 to $8 ahead of the Linaclotide PDUFA.

Cantor Fitzgerald said, "We reiterate our SELL rating going into the Linaclotide PDUFA: We remain cautiously optimistic about a first pass approval (we estimate 70% probability) but maintain that the stock is overvalued and could sell off even under a best- case scenario (since investors may play the event and then exit the stock post- approval due to lack of pending positive catalysts)."

Ironwood Pharmaceuticals closed at $12.29 on Friday.

Latest Ratings for IRWD

DateFirmActionFromTo
Aug 2016JP MorganMaintainsOverweight
Aug 2016BarclaysMaintainsEqual-weight
Apr 2016Cowen & Co.UpgradesMarket PerformOutperform

View More Analyst Ratings for IRWD
View the Latest Analyst Ratings

Posted-In: Cantor FitzgeraldAnalyst Color Price Target Reiteration Intraday Update Analyst Ratings

 

Related Articles (IRWD)

View Comments and Join the Discussion!